<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720340</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-2018-180</org_study_id>
    <nct_id>NCT03720340</nct_id>
  </id_info>
  <brief_title>Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis</brief_title>
  <official_title>The Open and Multi-center Phase III Clinical Study of Interleukin-11 in the Prevention and Treatment of Radioactive Oral Mucitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation induced oral mucositis which may result in reduced quality of life is commonly seen&#xD;
      during radiotherapy, especially combined with chemotherapy. This study is a prospective,&#xD;
      multicenter, and exploratory study. The aim of this study is to explore predictive factors of&#xD;
      acute radiotherapy induced oral mucositis in nasopharyngeal carcinoma patients treated with&#xD;
      radio-chemotherapy and reduce incidence of oral mucositis by using recombinant human&#xD;
      interleukin -11.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All nasopharyngeal patients received radical treatment including neo-adjuvant chemotherapy&#xD;
      and concurrent chemo-radiotherapy. Oral pharyngeal swabs and stool specimen were collected&#xD;
      3times:before neo-adjuvant chemotherapy,before concurrent chemo-radiotherapy and concurrent&#xD;
      chemo-radiotherapy finishied. Patients were randomly divided into two groups randomly. IL-11&#xD;
      was used in experience group and control group, saline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of severe acute radioactive oral mucitis</measure>
    <time_frame>through study completion, an average of 5mouth</time_frame>
    <description>Radiation Therapy Oncology Group/European Organization for research and treatment acute radiation morbidity scoring criteria. Grade 0: No change over baseline, Grade 1: Injection/ may experience mild pain not requiring analgesic, Grade 2: Patchy mucositis which may produce an inflammatory serosanguinitis discharge/ may experience moderate pain requiring analgesia, Grade 3: Confluent fibrinous mucositis/ may include severe pain requiring narcotic, Grade 4: Ulceration, hemorrhage or necrosis, Grade 5: death (Higher score equals to worse outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the occurrence time of severe acute radioactive oral mucitis in two groups</measure>
    <time_frame>first day from radiation to the date 3 degree acute radioactive oral mucitis occurred</time_frame>
    <description>RGOT/ CTCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>last period of severe acute radioactive oral mucitis</measure>
    <time_frame>through study completion, an average of 5month</time_frame>
    <description>RGOT/ CTCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oral flora</measure>
    <time_frame>through study completion, an average of 5month</time_frame>
    <description>Changes in oral flora during treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intestinal flora</measure>
    <time_frame>through study completion, an average of 5month</time_frame>
    <description>Changes in oral intestinal during treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>through study completion, an average of 5month</time_frame>
    <description>Nutrition Risk Screening NRS-2002 Assessment Comparison of Nutritional Status of Two Groups of Patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of quality of life</measure>
    <time_frame>through study completion, an average of 5month</time_frame>
    <description>Life Quality Measurement Scale H&amp;N35 Comparison of quality of life between two groups of patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Recombinant human interleukin-11</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Only 10ml 0.9% NS was administered twicely to patients through respiratory tract.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Interleukin-11</intervention_name>
    <description>Recombinant Human Interleukin-11 was administed through respiratory tract.</description>
    <arm_group_label>Recombinant human interleukin-11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>saline was administed through respiratory tract</description>
    <arm_group_label>Recombinant human interleukin-11</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of nasopharyngeal carcinoma.&#xD;
&#xD;
          2. 8th version American Joint Committee on Cancer (AJCC) stage I-IVB.&#xD;
&#xD;
          3. Age must beetween 18-75.&#xD;
&#xD;
          4. Performance status must be 0 or 1 according to Eastern Cooperative Oncology Group.&#xD;
&#xD;
          5. Adequate bone marrow, renal, and hepatic function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. chemotherapy with fluorouracil drugs; Allergies to recombinant human interleukin-11.&#xD;
&#xD;
          2. Treatment with palliative intent.;Previous malignancy.&#xD;
&#xD;
          3. Pregnancy or lactation.&#xD;
&#xD;
          4. A history of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to&#xD;
             the primary tumor or nodes.&#xD;
&#xD;
          5. Diabetes, oral mucositis and senile dry stomatitis.&#xD;
&#xD;
          6. Any severe coexisting disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanyuan Chen, Professor</last_name>
      <phone>+86 13738103808</phone>
      <email>chenyy@zjcc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Chen yuanyuan</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Acute Radiation Oral Mucositis</keyword>
  <keyword>Recombinant human interleukin-11</keyword>
  <keyword>oral microflora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oprelvekin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

